Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance UK
| ADXN Stock | CHF 0.06 0 4.84% |
Slightly above 61% of Addex Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Addex Therapeutics suggests that many traders are alarmed regarding Addex Therapeutics' prospects. Addex Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Addex Therapeutics' earnings reports, geopolitical events, and overall market trends.
Addex Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Addex daily returns and investor perception about the current price of Addex Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Addex |
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Yahoo Finance UK
Read at news.google.com
 |
Addex Therapeutics Fundamental Analysis
We analyze Addex Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Addex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Addex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Addex Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Addex Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Addex Therapeutics stock to make a market-neutral strategy. Peer analysis of Addex Therapeutics could also be used in its relative valuation, which is a method of valuing Addex Therapeutics by comparing valuation metrics with similar companies.
Peers
Addex Therapeutics Related Equities
| BEKN | Berner Kantonalbank | 1.29 | ||||
| LUKN | Luzerner Kantonalbank | 0.47 | ||||
| SGKN | St Galler | 0.34 | ||||
| BSKP | Basler Kantonalbank | 1.45 |
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.